Ashling Wahner

Associate Editor, OncLive

Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

Passion and Innovation Formed the Foundation for a Leading Cancer Program: With Girindra Raval, MD; and Anand Jillella, MD

October 15th 2025

Raval and Jillella discussed Jillella's career journey, starting from his oncology internship in 1989 to establishing a bone marrow transplant program.

Dr Le on the Efficacy of Firmonertinib for the Treatment of EGFR PACC–Mutated NSCLC

October 15th 2025

Xiuning Le, MD, PhD, discusses efficacy data with firmonertinib for the treatment of patients with EGFR PACC–mutated NSCLC.

Dr Le on the Prevalence of EGFR PACC Mutations in NSCLC

October 15th 2025

Xiuning Le, MD, PhD, discusses the prevalence of EGFR PACC mutations in NSCLC.

Acalabrutinib Plus Lenalidomide and Rituximab Is Safe and Active in Untreated Follicular Lymphoma

October 15th 2025

Acalabrutinib plus lenalidomide and rituximab displayed activity and had a tolerable safety profile in first-line follicular lymphoma.

Expanding Radioligand Options Redefine mCRPC Management and Individualize Patient Care

October 15th 2025

Alicia Morgans, MD, MPH, discusses the role of radioligand therapies for mCRPC and the importance of shared decision-making in prostate cancer management.

Adjuvant Chemoradiotherapy Yields 10-Year OS and RFS Advantages in High-Risk Endometrial Cancer

October 15th 2025

Chemoradiotherapy improved survival vs radiotherapy alone in the adjuvant setting in high-risk endometrial cancer, particularly in p53-abnormal disease.

Dr Lee on the Role of IMRT in Locally Advanced NSCLC Management

October 14th 2025

Percy Lee, MD, discusses the importance of considering radiation therapy techniques like IMRT and proton therapy for patients with locally advanced NSCLC.

PEACE-3 Data Add to Expanding Evidence Clarifying Radium-223 Use in mCRPC

October 14th 2025

Alicia Morgans, MD, MPH, discusses data from the PEACE-3 trial that support the use of radium-223 plus enzalutamide in patients with mCRPC.

Dr Gerds on the Distinct Mechanisms of Action of Approved JAK Inhibitors for Myelofibrosis

October 14th 2025

Aaron T. Gerds, MD, MS, discusses the mechanisms of action of the 4 FDA-approved JAK inhibitors available for the treatment of patients with myelofibrosis.

Dr Mouhieddine on Ferritin and ALC As Markers of Bispecific Antibody Response in Myeloma

October 14th 2025

Tarek Mouhieddine, MD, discusses the use of ferritin and ALC as biomarkers of response to bispecific antibodies in relapsed/refractory multiple myeloma.

Teclistamab-Based Induction Regimens Deepen Responses in Newly Diagnosed Multiple Myeloma

October 14th 2025

Marc S. Raab, MD, discusses updated MRD negativity and safety data with teclistamab plus SOC induction regimens in newly diagnosed multiple myeloma.

Oncology Experts Preview Key Studies Ahead of the 2025 ESMO Congress

October 13th 2025

Leading experts across oncology specialties preview the key studies and data they are most anticipating ahead of the 2025 ESMO Congress.

CELMoDs Could Augment T-Cell Redirection Therapies for Prolonged Remission in R/R Myeloma

October 13th 2025

Joshua Richter, MD, discusses the use of next-generation CELMoDs to boost T-cell responses with bispecific antibodies or CAR T-cell therapy in myeloma.

Real-World Study Shows Highest Treatment Adherence Rates With Zanubrutinib vs Other BTK Inhibitors in MCL

October 13th 2025

Real-world MCL treatment with zanubrutinib generated longer treatment durations and higher treatment adherence rates vs acalabrutinib and ibrutinib.

FDA Approval Insights: Gemcitabine Intravesical System for NMIBC: With Joseph Jacob, MD, MCR

October 9th 2025

Dr Jacob discusses the significance of the FDA approval of the gemcitabine intravesical system for BCG-unresponsive non–muscle-invasive bladder cancer.

Dr Randall on the Benefits and Limitations of MRI in Soft Tissue Sarcoma Surveillance

October 9th 2025

R. Lor Randall, MD, FACS, discusses the current paradigm and future trajectory of imaging modalities for the surveillance of soft tissue sarcoma.

Dr Tarantino on the CompassHER2 pCR Trial of THP in HER2+ Breast Cancer

October 9th 2025

Paolo Tarantino, MD, PhD, discusses the design and background of the CompassHER2 pCR trial of THP in HER2-positive breast cancer.

Fruquintinib Represents Viable Later-Line Option for mCRC As Access Expands for Patients

October 9th 2025

Kanwal P.S. Raghav, MBBS, MD, discusses the role of fruquintinib for the treatment of patients with later-line colorectal cancer.

ESMO 2025 Will See Novel Agents Emerge and Standard Strategies Shift in GI Oncology

October 9th 2025

Ahead of the 2025 ESMO Congress, GI cancer experts share the gastric cancer and CRC research they’re most looking forward to seeing at the meeting.

Poor Response Rates Persist After Progression on Brexu-Cel in Mantle Cell Lymphoma

October 9th 2025

Patients with MCL who relapsed after brexu-cel had poor survival outcomes, underscoring the need for effective post–CAR T-cell therapy strategies.